<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00384228</url>
  </required_header>
  <id_info>
    <org_study_id>CAMN107A1101</org_study_id>
    <nct_id>NCT00384228</nct_id>
  </id_info>
  <brief_title>A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL</brief_title>
  <official_title>A Phase I/II Multicenter, Dose-escalation Study of Oral Nilotinib on a Continuous Daily Dosing Schedule in Adult Patients With Imatinib-resistant or Imatinib-intolerant CML, or Relapse/Refractory Ph+ALL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will investigate if nilotinib provides an improved safety and efficacy profile
      over that seen in patients receiving Imatinib.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety evaluation assessed by dose limiting toxicity within first cycle of 28 day treatment and AEs within 3 cycles</measure>
    <time_frame>every first 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) profile of single and multiple doses</measure>
    <time_frame>day 1 and 15 of cycle 1,day 6, 8, 10, 12, 22 and 28 of cycle 1, day 15 of cycle 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-leukemic activity within 3 cycles of 28 days treatment</measure>
    <time_frame>Day 28 cycle 1, 2 and 3, at the time of disease progression, and at the time of study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone marrow and/or blood assessments to detect the presence of Bcr-Abl transcript and mutational analysis of Bcr-Abl before, during and after therapy.</measure>
    <time_frame>Day 28 cycle 1, 2 and 3, at the time of disease progression, and at the time of study comp</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)</condition>
  <arm_group>
    <arm_group_label>Nilotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <arm_group_label>Nilotinib</arm_group_label>
    <other_name>AMN107</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed as Ph+ ALL who are either relapsed after or refractory to standard therapy

          -  Diagnosed as CML in blast crisis or accelerated phase or chronic phase who are
             resistant or intolerant to imatinib

          -  Performance status is normal or ambulatory and capable of all self-care Exclusion
             Criteria

          -  A history of significant or serious uncontrolled cardiovascular disease

          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of nilotinib

          -  Patients who are pregnant or breast feeding, or adults of reproductive potential not
             employing an effective method of birth control

        Exclusion Criteria:

          -  Cytopathologically confirmed CNS infiltration NB: in absence of suspicion of CNS
             involvement, lumbar puncture is not required

          -  Impaired cardiac function, including any one of the following

               -  LVEF &lt; 45% as determined by echocardiogram

               -  Complete left bundle branch block

               -  Use of a cardiac pacemaker

               -  ST depression of &gt; 1mm in 2 or more leads and/or T-wave inversions in 2 or more
                  contiguous leads

               -  Congenital long QT syndrome

               -  History of or presence of significant ventricular or atrial tachyarrhythmias

               -  Clinically significant resting bradycardia (&lt; 50 beats per minute)

               -  QTc &gt; 480 msec on screening ECG (using the QTcF formula)

               -  Right bundle branch block plus left anterior hemiblock, bifascicular block

               -  Myocardial infarction within 3 months prior to starting AMN107

               -  Uncontrolled angina pectoris

          -  Other clinically significant heart disease (e.g., congestive heart failure,
             uncontrolled hypertension, history of labile hypertension, or history of poor
             compliance with an antihypertensive regimen)

          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of AMN107 (e.g. ulcerative diseases, uncontrolled nausea,
             vomiting, diarrhea, malabsorption syndrome, or small bowel resection)

          -  Use of therapeutic warfarin

          -  Acute or chronic liver or renal disease considered unrelated to tumor (e.g.,
             hepatitis, cirrhosis, renal insufficiency, etc.)

          -  Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled
             diabetes, active or uncontrolled infection) that could cause unacceptable safety risks
             or compromise compliance with the protocol

          -  Treatment with any hematopoietic colony-stimulating growth factors (e.g., G-CSF) ≤ 1
             week prior to starting study drug.

          -  Patients who are currently receiving treatment with any of the medications listed in
             (cf. Post-text suppl. 5) that cannot be either discontinued or switched to a different
             medication prior to starting study drug. The medications listed in (cf. Post-text
             suppl. 5) have the potential to prolong the Q-T interval.

          -  Patients who have received chemotherapy ≤ 1 week or who are within 5 half-lives of
             their last dose chemotherapy (6 weeks for nitrosurea or mitomycin-C) prior to starting
             study drug or who have not recovered from side effects of such therapy. Hydroxyurea is
             permitted at the investigator's discretion prior to enrollment.

          -  Patients who have received Glivec® ≤ 1 week or who have not recovered from side
             effects of such therapy.

          -  Patients who have received immunotherapy ≤ 1 week prior to starting study drug or who
             have not recovered from side effects of such therapy.

          -  Patients who have received any investigational drug (excluding STI571/Glivec) ≤ 4
             weeks or investigational cytotoxic agent within 1 week (or who are within 5 half-lives
             of a previous investigational cytotoxic agent) prior to starting study drug or who
             have not recovered from side effects of such therapy.

          -  Patients who have received wide field radiotherapy ≤ 4 week or limited field radiation
             for palliation ≤ 2 week prior to starting study drug or who have not recovered from
             side effects of such therapy.

          -  Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or
             who have not recovered from side effects of such therapy.

          -  Patients who are pregnant or breast feeding, or adults of reproductive potential not
             employing an effective method of birth control. (Women of childbearing potential must
             have a negative serum pregnancy test within 48 hrs prior to administration of AMN107).
             Post-menopausal women must be amenorrheic for at least 12 months to be considered of
             non-childbearing potential. Male and female patients must agree to employ an effective
             barrier method of birth control throughout the study and for up to 3 months following
             discontinuation of study drug

          -  Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not
             mandatory)

          -  Patients with a history of another primary malignancy that is currently clinically
             significant or currently requires active intervention.

          -  Patients unwilling or unable to comply with the protocol

        Other protocol-defined inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2006</study_first_submitted>
  <study_first_submitted_qc>October 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2006</study_first_posted>
  <last_update_submitted>April 11, 2012</last_update_submitted>
  <last_update_submitted_qc>April 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Myelogenous Leukemia</keyword>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

